1Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006;25:419-25.
2Zilberberg MD, Shorr AF, Kollef MH. Secular Trends in Candidemia-Related Hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol. 2008;29:978-80.
3Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-43.
4Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002;50:243-60.
5Ghannoum MA, Roilides E, Katragkou A, Petraitis V, Walsh TJ. The role of echinocandins in Candida biofilm-related vascular catheter infections: in vitro and in vivo model systems. Clin Infect Dis. 2015;61(Suppl 6):618-21.
6Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106:523-9.
7Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-3.
8Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, Kollef MH. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med. 2007;35:1077-83.
9Hankovszky P, Trasy D, Öveges N, Molnar Z. Invasive Candida infections in the ICU: Diagnosis and therapy. J Crit Care Med (Targu Mures). 2015;1:129-39.
10Terlecka JA, du Cros PA, Morrissey CO, Spelman D. Rapid differentiation of Candida albicans from non‐albicans species by germ tube test directly from BacTAlert blood culture bottles. Mycoses. 2007;50:48-51.
11Salazar JM, Rojas R. Comparative study for identification of Candida albicans with germ tube test in human serum and plasma. Clinical Microbiology and Infectious Diseases. 2018;3:1-4.
12Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2012 (Document M27-S4).
13Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2008 (Approved standard M27-S3).
14Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E; Candidemia Study Group. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection. 2016;44:205-13.
15Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45-8.
16Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients, Clin Microbiol Infect. 2012;18(Suppl 7):19-37.
17Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739-46.
18Aydemir Ö, Demiray T, Köroğlu M, Aydemir Y, Altındiş M. Emerge of non-albicans Candida species; evaluation of Candida species and antifungal susceptibilities according to years. Biomedical Research. 2017;28:1-6.
19Doğan Ö, Gülmez D, Arıkan Akdağlı Arıkan S. A Fast Preliminary Identification Test in Fungemia: Evaluation of Germ Tube Test Directly from Positive Blood Culture Bottles. Ankem Derg. 2016;30:102-8.
20Gokbolat E, Oz Y, Metintas S. Evaluation of three different bottles in BACTEC 9240 automated blood culture system and direct identification of Candida species to shorten the turnaround time of blood culture. J Med Microbiol. 2017;66:470-6.
21Sheppard DC, Locas MC, Restieri C, Laverdiere M. Utility of the germ tube test for direct identification of Candida albicans from positive blood culture bottles. J Clin Microbiol. 2008;46:3508-9.
22Saad U, Siddiqui S, Jamil N, Jamil S, Hafiz S. Detection of Candida albicans from Positive Blood Culture Bottles. Int J Pathol. 2013;11:54-7.
23Kassim A, Pflüger V, Premji Z, Daubenberger C, Revathi G. Comparison of biomarker based Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) and conventional methods in the identification of clinically relevant bacteria and yeast. BMC Microbiol. 2017;17:128.
24Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:1-50.
25Chi HW, Yang YS, Shang ST, Chen KH, Yeh KM, Chang FY, Lin JC. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect. 2011;44:369-75
26Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging Non-albicans Candida species. Front Microbiol. 2016;7:2173
27Tulumoğlu Ş, Kariptaş E, Belgin E. Identification and antifungal susceptibility of Candida isolates from various clinical specimens in Doctor Behcet Uz Hospital. Anatol J Clin Invest. 2009;3:170-3.